Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer*

The receptor tyrosine kinase ErbB2 (HER-2/neu) is overexpressed in up to 30% of breast cancers and is associated with poor prognosis and an increased likelihood of metastasis especially in node-positive tumors. In this proteomic study, to identify the proteins that are associated with the aggressive phenotype of HER-2/neu-positive breast cancer, tumor cells from both HER-2/neu-positive and -negative tumors were procured by laser capture microdissection. Differentially expressed proteins in the two subsets of tumors were identified by two-dimensional electrophoresis and MALDI-TOF/TOF MS/MS. We found differential expression of several key cell cycle modulators, which were linked with increased proliferation of the HER-2/neu-overexpressing cells. Nine proteins involved in glycolysis (triose-phosphate isomerase (TPI), phosphoglycerate kinase 1 (PGK1), and enolase 1 (ENO1)), lipid synthesis (fatty acid synthase (FASN)), stress-mediated chaperonage (heat shock protein 27 (Hsp27)), and antioxidant and detoxification pathways (haptoglobin, aldo-keto reductase (AKR), glyoxalase I (GLO), and prolyl-4-hydrolase β-isoform (P4HB)) were found to be up-regulated in HER-2/neu-positive breast tumors. HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment. Statistical correlations of these protein expressions with HER-2/neu status were further verified by immunohistochemistry on a tissue microarray comprising 97 breast tumors. Our findings suggest that HER-2/neu signaling may result, directly or indirectly, in enhanced activation of various metabolic, stress-responsive, antioxidative, and detoxification processes within the breast tumor microenvironment. We hypothesize that these identified changes in the cellular proteome are likely to drive cell proliferation and tissue invasion and that the key cell cycle modulators involved, when uncovered by future research, would serve as naturally useful targets for the development of therapeutic strategies to negate the metastatic potential of HER-2/neu-positive breast tumors.

[1]  Joseph Geradts,et al.  Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. , 2002, The American journal of pathology.

[2]  S. Gonin,et al.  Hsp27 as a Negative Regulator of Cytochrome c Release , 2002, Molecular and Cellular Biology.

[3]  T. Tomonaga,et al.  Identification of Altered Protein Expression and Post-Translational Modifications in Primary Colorectal Cancer by Using Agarose Two-Dimensional Gel Electrophoresis , 2004, Clinical Cancer Research.

[4]  M. Knowles,et al.  Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect , 2003, Proteomics.

[5]  C. Concannon,et al.  On the role of Hsp27 in regulating apoptosis , 2004, Apoptosis.

[6]  Qing‐Yu He,et al.  Proteomics of buccal squamous cell carcinoma: The involvement of multiple pathways in tumorigenesis , 2004, Proteomics.

[7]  Allison Jones,et al.  cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.

[8]  P. Hogg,et al.  Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase , 2000, Nature.

[9]  P. Visca,et al.  Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. , 2004, Gynecologic oncology.

[10]  E. Rogaev,et al.  Role for glyoxalase I in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Gago,et al.  Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy , 1998, International journal of cancer.

[12]  A. Chinnaiyan,et al.  Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. , 2003, Cancer research.

[13]  Rainer Cramer,et al.  Evaluation of Two-dimensional Differential Gel Electrophoresis for Proteomic Expression Analysis of a Model Breast Cancer Cell System* , 2002, Molecular & Cellular Proteomics.

[14]  T. Tsuruo,et al.  Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Waterfield,et al.  Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression , 2004, British Journal of Cancer.

[16]  S. Devries,et al.  Genetic alterations in ERBB2-amplified breast carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[18]  Manuel Salto-Tellez,et al.  Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. , 2003, Human pathology.

[19]  Masaaki Ito,et al.  Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer , 2004, Clinical Cancer Research.

[20]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[21]  T. Tsuruo,et al.  Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. , 2000, Blood.

[22]  D. Chan,et al.  Identification of tumor‐associated plasma biomarkers using proteomic techniques: From mouse to human , 2004, Proteomics.

[23]  Takashi Tsuruo,et al.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal , 2003, Cancer science.

[24]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[25]  G. Rice,et al.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer , 2004, British Journal of Cancer.

[26]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.

[27]  J. Mendelsohn,et al.  Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase* , 1998, The Journal of Biological Chemistry.

[28]  N. Cordani,et al.  Expression of heat shock protein 27 in human renal cell carcinoma , 2004, Proteomics.

[29]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[30]  Suzuki Toshimitsu,et al.  Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Jun Yu,et al.  Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. , 2004, Journal of proteome research.

[32]  L. Witters,et al.  Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Menéndez,et al.  Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogene‐induced malignant transformation , 2004, Molecular carcinogenesis.

[34]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[35]  P. Huppert,et al.  Expression of hypoxia-inducible genes in tumor cells , 1998, Journal of Cancer Research and Clinical Oncology.

[36]  M. Gleave,et al.  Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer , 2004, Cancer Research.

[37]  S. Ropero,et al.  Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Mong-Hong Lee,et al.  Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth , 2004, Oncogene.

[39]  S. Love,et al.  A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. , 1994, British Journal of Cancer.

[40]  F. Preffer,et al.  Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. , 2002, Anticancer research.

[41]  A. Al Moustafa,et al.  The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[42]  Dao-Hai Zhang,et al.  Proteomics of breast cancer: Enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors , 2005, Proteomics.

[43]  O. Popanda,et al.  Modulation of DNA polymerases α, δ and ε by lactate dehydrogenase and 3-phosphoglycerate kinase , 1998 .